FIELD: chemistry.
SUBSTANCE: invention describes novel compounds of formula 
where values of radicals are given in the formula of invention, and a pharmaceutically acceptable salt thereof. Said compounds have 17β-hydroxysteroid dehydrogenase enzyme (17β-HSD) inhibiting activity. The invention describes use of the formula (I) compound in treating or preventing diseases or disorders which require inhibition of 17β- hydroxysteroid dehydrogenase enzyme, use of the formula (I) compound to prepare a medicinal agent for treating or preventing diseases or disorders which require inhibition of 17β- hydroxysteroid dehydrogenase enzyme, and a pharmaceutical composition based on the formula (I) compound.
EFFECT: derivatives are highly effective.
18 cl, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUNDS AND USE THEREOF IN THERAPY | 2004 |
|
RU2412190C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING BENZODIAZEPINE DERIVATIVES AND RSV FUSION PROTEIN INHIBITOR | 2005 |
|
RU2388476C2 |
| NOVEL DERIVATIVES OF BENZIMIDAZOLE AND THEIR USING AS MEDICAMENTS | 2002 |
|
RU2294326C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| NEW INHIBITORS OF 17 β-HYDROXYSTEROID-DEHYDROGENASE TYPE I | 2004 |
|
RU2369614C2 |
| DERIVATIVES OF BETA-CARBOLINE POSSESSING EFFECT OF PHOSPHODIESTERASE INHIBITORS, PHARMACEUTICAL COMPOSITION (VARIANTS), METHOD FOR ITS PREPARING, METHOD FOR INHIBITION OF PHOSPHODIESTERASE EFFECT (VARIANTS) AND METHOD FOR INCREASING CGMP CONCENTRATION | 2001 |
|
RU2271358C2 |
| 17β-HSD1 AND STS INHIBITORS | 2006 |
|
RU2412196C2 |
| POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | 2017 |
|
RU2750935C2 |
| DERIVATIVES OF QUINOLINE XANTHINE AND 8-ISOQUINOLINE XANTHINE AS INHIBITORS OF PHOSPHODIESTERASE PDE-5 | 2001 |
|
RU2269529C2 |
| CONDENSED PIRIMIDINE DERIVATIVE AND PHARMACEUTICS WITH CRF RELATED ACTIVITY | 2004 |
|
RU2328497C2 |
